Randomized, double blind, placebo controlled clinical study for evaluating the efficacy of a food supplement on cellulite-derived skin imperfections and weight control

ROELMI HPC Srl0 个研究点目标入组 60 人开始时间: 2018年7月24日最近更新: 2019年12月10日

试验速览

暂无简介。

•1. Good general health
•3. Caucasian ethnicity
•4. Age between 18 and 55 years old
•5. Mild to moderate cellulite-derived skin imperfections (grade II and III of the cellulite thermographic stage)
•6. BMI between 23 and 30.
•7. Not been recently involved in any other similar study
•8. Willing to follow the proposed alimentary diet for all the study time
•9. Willing to use only the cream consigned at the beginning of the study for body care
•10. Willing to submit to before and after pictures
•11. Willing to use only the food supplement during the entire study period
•12. Willing to not use products likely to interfere with the food supplement
•13. Willing to not vary the normal daily routine (i.e. lifestyle, physical activity, etc.)
•14. Under effective contraception (oral/not oral) that is not expected to be changed during the trial
•15. Aware of study procedures and signed informed consent form

•1. Pregnant or intending to become pregnant during study
•2. Breastfeeding
•3. Atopy (if this interferes with the study)
•4. Allergic to ingredients of food supplements
•5. Allergies to cosmetic products, toiletries, sunscreens and/or topical drugs
•6. Following anti-cellulite treatment or have followed an anti-cellulite treatment less than 3 months before the study
•7. Used sunbeds or self-tanning product for one month before study or intend to use it during the study
•8. Using pharmacological treatment (local or systemic) that may interfere with study
•9. Intending to initiate any intensive sport
•10. Other diseases that may affect outcome of study, especially metabolic or endocrine (e.g. diabetes, liver disease, kidney disorders) or any other condition that the principal investigator deems inappropriate for participation
•11. Protected by the law (under guardianship, hospitalised in a public or private institution or incarcerated)
•12. Unable to communicate or cooperate with the investigator

发起方

ROELMI HPC Srl